This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (22)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Oncology, Other  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

The University of Rochester Experience

Dennis Blom, MD; Seymour I. Schwartz, MD,FACS

Arch Surg. 2001;136:209-214.

Hypothesis  To our knowledge, few individual surgeons and only a handful of institutions have gained a meaningful experience with the treatment of adenocarcinoma of the extrahepatic bile ducts or cholangiocarcinoma. The purpose of this study was to critically evaluate the experience of a single center in the treatment of these tumors.

Design  Retrospective cohort study with a median follow-up of 48 months.

Setting  Department of surgery at a university referral center.

Patients  Seventy-seven patients with biopsy-confirmed adenocarcinoma of the extrahepatic bile ducts evaluated and treated between January 1980 and February 1998.

Main Outcome Measures  Prognostic variables, resectability rates, morbidity, and survival.

Results  Thirty-eight male and 39 female patients were studied (median age, 71 years). Twenty-three patients (30%) underwent curative resections, 32 patients (41%) underwent palliative surgery, and 22 patients (29%) received nonoperative therapies. The 30-day perioperative morbidity rate was 18%, and mortality was 6%. Overall median survival was 11 months; 4 months for patients receiving nonoperative therapy; 8 months for patients recieving palliative surgery; and 72 months for curative resection. Five-year survival rates were 23%, 0%, 10%, and 55%, respectively. Curative resection was the only prognostic variable to have a statistically significant effect on survival.

Conclusions  Curative resection could be achieved in approximately one third of patients who had cholangiocarcinoma, and should be the goal of treatment. Survival is significantly improved in those patients who are considered to have resectable tumors and who undergo removal of all gross disease. Palliative surgical treatments also revealed a survival advantage over nonoperative therapies.

From the Department of Surgery, University of Southern California, Los Angeles (Dr Blom); and the Department of Surgery, University of Rochester, Rochester, NY (Dr Schwartz).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Invited Critique
Gerald W. Peskin
Arch Surg. 2001;136(2):215.
EXTRACT | FULL TEXT